Luminex logo

LMNX - Luminex News Story

$32.95 0.7  2.1%

Last Trade - 09/04/21

Mid Cap
Market Cap £1.14bn
Enterprise Value £1.06bn
Revenue £304.5m
Position in Universe 2442nd / 6827

FACTBOX-U.S. pours billions into securing access to coronavirus vaccine candidates

Wed 22nd July, 2020 6:13pm
(Adds deal for Pfizer-BioNTech vaccine)
    July 22 (Reuters) - As drugmakers race to develop vaccines and therapies for the novel coronavirus, the United States is rushing to secure access to them.
    The U.S. government will pay $1.95 billion to buy 100 million doses of a COVID-19 vaccine being developed by Pfizer Inc  PFE.N  and German biotech BioNTech SE
 22UAy.F  if it proves to be safe and effective. The contract is the most the United States has agreed to spend on a vaccine, under "Operation Warp Speed," the White
House program aimed at accelerating access to vaccines and treatments for the new coronavirus. Previous deals with other vaccine makers were intended to also help pay for
development costs.
    The U.S. government has agreed to invest more than $5 billion in vaccines and has funded more than 30 projects, including for diagnostics and treatments. The agency
has awarded grants to Moderna, the first in the United States to begin human trials of a coronavirus vaccine, Sanofi, the world's largest vaccine maker, and Johnson &
Johnson  JNJ.N .  
    The following tables list publicly disclosed funding of over $1 million from the Biomedical Advanced Research and Development Authority (BARDA), a U.S. federal agency
that funds disease-fighting technology:
 Company                   BARDA Funding     Vaccine type                                        Stage of development
 Pfizer Inc  PFE.N  and    $1.95 bln         Uses the so-called messenger RNA approach that      Mid-stage trial to begin late July, companies expect some form of
 BioNTech SE  22UAy.F                        sets off an immune response to target the virus     regulatory approval as early as October and aim to make up to 100
                                                                                                 million doses by end of 2020 and potentially more than 1.2 billion
                                                                                                 doses by end of 2021
 Novavax Inc  NVAX.O       $1.6 bln          Works with an adjuvant - a substance that boosts    Mid-stage trials to begin in August or September, late-stage in
                                             immune response to help body build a robust         October. Grant covers testing, commercialization and manufacturing of
                                             defense against the virus                           vaccine in U.S., with aim of delivering 100 mln doses by January 
 AstraZeneca Plc  AZN.L    up to $1.2 bln    AZD1222 was developed by the University of Oxford   Mid-stage trials underway
                                             and licensed to AstraZeneca                         
 Moderna Plc  MRNA.O       $486 mln          mRNA-1273 - uses synthetic messenger RNA (mRNA) to  Vaccine produced positive results in 45-subject safety trial;
                                             inoculate against the coronavirus                   late-stage trial to start in July 
 Johnson & Johnson         $456.2 mln        Viral Vector Vaccine for COVID-19 - uses pharma     Early stage trials to start in July, late-stage study planned for
  JNJ.N                                      unit Janssen Research's established Adenovirus 26   September
 Merck & Co Inc  MRK.N     $38 mln           Recombinant COVID-19 vaccine - Based on same        Human trials for vaccine, being developed jointly with research
                                             technology used in co's Ebola vaccine ERVEBO        nonprofit IAVI, expected sometime this year
 Sanofi SA  SASY.PA        $30.7 mln         Recombinant SARS-CoV-2 Protein Vaccine -  Based on  Plans to enroll 1000s of subjects globally for early-stage trials for
                                             co's FDA-licensed seasonal influenza vaccine        the vaccine it is developing with GlaxoSmithKline Plc  GSK.L 
 *Sanofi is also working with U.S.-based Translate Bio Inc  TBIO.O  on another vaccine candidate based on messenger RNA technology (mRNA). This vaccine has not received
funding from BARDA.
 Company                    BARDA Funding    Therapy type                                        Stage of development
 Regeneron Pharmaceuticals  $85 mln and      SARS-CoV-2 specific monoclonal antibodies - A       Antibody being tested for preventing and treating COVID-19, late-stage
  REGN.O                    $450 mln         therapeutic antibody cocktail using Regeneron's     prevention trial run jointly with National Institutes of Health 
                                             discovery platform VelocImmune                      
                                                                                                 $450 mln contract to cover manufacture and supply of a fixed number of
                                                                                                 bulk lots of the antibody cocktail, to be completed in fall of 2020
 Johnson & Johnson  JNJ.N   $152 mln         Janssen Research & Development and Rega Institute   No development details available
                                             of Medical Research to screen libraries to          
                                             identify therapeutic compounds with antiviral       
                                             activity against COVID-19.                          
 Genentech USA  ROG.S       $25.1 mln        Repurposing its rheumatoid arthritis therapy,       Regulatory nod for late-stage clinical trial to study efficacy along with
                                             Actemra(tocilizumab), to help control               standard of care in hospitalized adult patients with severe COVID-19
                                             COVID-19-associated inflammation that could cause   pneumonia
                                             respiratory failure                                 
 AstraZeneca  AZN.L         $23.6 mln        Novel monoclonal antibody combination that          Grant supports company’s efforts to develop the treatment, including
                                             recognizes and neutralizes SARS-CoV-2               early clinical trial and manufacturing of investigational product for
 Emergent Biosolutions      $14.5 mln        Treatment based on plasma from recovered COVID-19   Planning clinical trials 
  EBS.N                                      patients                                            
 Grifols Shared Services    $12.5 mln        Treatment based on plasma donated by patients who   Company collecting plasma samples. Human studies yet to begin
 North America                               have recovered from COVID-19; plasma contains       
                                             antibodies that can target the virus                
 SAb Biotherapeutics        $7.2 mln         Immunotherapy that uses SAb's technology to         Human trials have not started. Company says it has finished preclinical
                                             produce COVID-19 antibodies without blood           studies 
                                             donations from recovered people                     
Source: BARDA website (, U.S. FDA as well as company press releases

 (Reporting By Vishwadha Chander and Mrinalika Roy in Bengaluru; Editing by Ankur Banerjee and  Sriraj Kalluvila)
 ((; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.